Curing Infectious DiseasesSept.,2013

Our First Target is Dengue Fever

1

400 Million Dengue Infections Annually

2CDC-HeathMap Collaboration, http://www.healthmap.org/dengue/index.php

We Have A Cure For Dengue

3

Control Neutralizing Serum

A Control

Peptide 57

B Control

Peptide ETX-101

C

>99% Inhibition

ETX-101 Mechanism of Action

4

Issued, Filed or Pending Patents

5

Dengue Products In Development

6

Our Expert Team

7

Robert F. Garry, Ph.D.Inventor – 30 YrsChief Science Officer

Elizabeth Moore, RPh30 Yrs Experience Gov’t/IndustryRegulatory Affairs

Darnisha HarrisonMicrobiologist/Bus. Dev Licensing – 19yrsPresident & CEO

Scott Michael, Ph.D.Co-inventor – 15 YrsScientific Advisor

SUPPORT TEAM

Adrian Barfied23 YrsPharma EntrepreneurRomeo Ibrahim20 YrsProcess ScientistThandeka Myeni, MD14 YrsMedical AdvisorGeorge Davis20 YrsCorporate Affairs

TIBA OncologyP4 Healthcare

Dengue Therapeutic Development Plan

8

Preclinical Preparation

EffectivenessNon-Human

Primates

Pre-IND Meeting

Safety/Toxicity Non-Human

PrimatesIND

SubmissionPhase I/IIa

Clinical TrialPhase I/IIa Data

Retrieval & Publishing

July 2013 Jan 2014 May 2014 Mar 2015 July 2015 May 2016 Oct 2016

$35K $3.7M $265K $3.75M $250K $11M $1M

$4,000,000 $4,000,000 $12,000,000

Market Potential

9

$63 Per Dose

$0

$500

$1,000

$1,500

$2,000

Year 1 Year 2 Year 3 Year 4 Year 5

$1.69 Billion

40%

40%

40%

40%

40%

Economic Savings

Revenue In Millions

Monetization/Exit Strategies

10

Dengue Is Just The Beginning

11

West Nile Virus Hepatitis C

30M Annual Infections 170M Annual Infections

200M Additional Doses

Thank YouI Trust That I Have Thoroughly Convinced You That Ennaid Has The Solution, The Plan & The Team To Develop Cures For All Four Strains Of Dengue Virus, Followed by Hepatitis C Virus & West Nile Virus.